Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Spring;7(2):108–117.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Research Institute for Gastroenterology and Liver Diseases

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

PMC Copyright notice

Results of antibody isotyping. Sera were collected 2 weeks after the last immunization and serial dilutions of sera from 1/100 to 1/204800 were used. A) Significant decrease in IgG1 titer appeared to be in order of: HBV vaccine ∼ HBV vaccine plus 2.5µg of melittin > HBV vaccine plus 5µg or 10µg melittin (∼ means no significant difference). B) Immunization of mice with HBV vaccine plus 2.5µg, 5µg, or 10µg melittin decreased IgG2a titer in comparison to HBV vaccine-immunized group. The significant decrease in IgG2a titer appeared to be in order of: HBV vaccine > HBV vaccine plus 2.5µg melittin > HBV vaccine plus10µg melittin > HBV vaccine plus 5 µg melittin. C) IgG2b titer was not significantly different among HBV vaccine plus 2.5µg, 5µg, or 10µg melittin and HBV vaccine-immunized groups. D) Immunization of mice with HBV vaccine plus 10µg melittin significantly increased IgM titer in comparison to HBV vaccine-immunized group.